



THE BLACK VAULT

This document was obtained from The Black Vault, an online database of declassified government documents. This particular record is housed in the MKULTRA/Mind Control Collection, a compilation of more than 20,000 pages declassified by the Central Intelligence Agency (CIA).

The entire collection is free to download and online at:

<http://mkultra.theblackvault.com>

**SANDOZ
PHARMACEUTICALS**

**DIVISION OF INC.
HANOVER, NEW JERSEY**

October 23, 1957

116

Harris Isbell, M.D.
National Institute of Mental Health
Addiction Research Center
U.S. Public Health Service Hospital
P.O. Box 207C
Lexington, Kentucky

Dear Doctor Isbell:

I am pleased to hear that you are interested in the
Sandoz products which are being developed for the treatment of
addiction. I am sure that you will find them of great value.

With my very best regards, I am,

Yours most sincerely,

R. Richter, M.D.
Medical Director.

RD/CH.
Encl.

4-407

A-402

	DL 25	DL 61	DL 74	DL 75	DL 76
<u>Toxicity</u> DL 50 rats mg/kg (rabbit)	5.0 (17)	[LD ₅₀ > 15.0]	9.5 (31)	7.5 (26)	0.3 (11)
<u>Paragonia effect</u> (rabbit, 1cc) compared to 100 25 = 1	1/105	[1/750]	1/250	1/100	1
<u>Serotonin antinociception</u> (isolated rat stomach) compared to 100 25 = 1	1/150	5.13	6.25	1.1	1
<u>Solubility</u>	1% aqueous solution	NBL 61 2 parts tartaric acid 1 part water 100 parts	1% aqueous solution	1% aqueous solution	

* NBL 61 produces a diminution of body temperature. The decrease is of the same order of magnitude as the increase produced by 1/100 times the Max dose of LSD 25.